Bio-Thera Solutions, Ltd. Class A

As of June 30, 2026, Bio-Thera Solutions, Ltd. Class A carries a market capitalization of 6.96B, placing it among publicly traded companies globally. Its enterprise value stands at 7.47B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Bio-Thera Solutions, Ltd. Class A's next confirmed earnings release is scheduled for October 28, 2026.

As of June 30, 2026, Bio-Thera Solutions, Ltd. Class A has 414.08M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 6.91, and the price-to-book ratio stands at 56.19.

These figures are as of June 30, 2026. The EV/Sales ratio of 7.43 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 7.47B versus a market cap of 6.96B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Bio-Thera Solutions, Ltd. Class A maintains a current ratio of 0.65, meaning it holds 0.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 724.54, indicating elevated leverage, while an interest coverage ratio of -21.20 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Bio-Thera Solutions, Ltd. Class A posted a negative return on equity (ROE) of -106.04, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -15.92, reflecting losses generated across the asset base. The company generates approximately 727,444.64 in revenue per employee across its workforce of 1,382.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.63 indicates how many times Bio-Thera Solutions, Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Bio-Thera Solutions, Ltd. Class A recorded 268,694.64 in income tax expense. The company reported a pretax loss of -391.22M and -391.65M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, Bio-Thera Solutions, Ltd. Class A's stock has declined approximately 32.02% over the past 52 weeks. The 50-day moving average sits at 18.80, while the 200-day moving average is 20.43.

Over the twelve months ended June 30, 2026, Bio-Thera Solutions, Ltd. Class A generated 1.01B in revenue and converted that into -391.65M in net income, yielding earnings per share of -0.95. EBITDA reached -423.26M, while operating income came in at -400.09M.

As of June 30, 2026, Bio-Thera Solutions, Ltd. Class A holds 395.52M in cash and equivalents against 898.00M in total debt, resulting in a net debt position of 256.21M. Total book value stands at 123.94M, with working capital of -610.96M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Bio-Thera Solutions, Ltd. Class A posted a gross margin of 80.03, reflecting its pricing power and cost economics. The operating margin of -39.79 and net profit margin of -38.95 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Bio-Thera Solutions, Ltd. Class A paid dividends of 0.05 per share. The dividend payout ratio of -5.19 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield is negative at -2.42, meaning Bio-Thera Solutions, Ltd. Class A raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Bio-Thera Solutions, Ltd. Class A has an Altman Z-Score of -0.79, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.